APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Early use of Anti-Fibrotics and the benefits to patients (Prof. Luca Richeldi & Prof. Toby Maher)
Document ID: PC-MY-102194
18/07/2022
Author: Boehringer Ingelheim
RELATED CONTENT
PC-MY-102194
Production date: July 2022
Production date: July 2022